Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > Amendment to trial design
View:
Post by jeffm34 on Apr 15, 2022 1:28am

Amendment to trial design

This appears to have been added into the latest trial design amendment updated yesterday. Must have been something they've seen already in the phase 1a. Under exclusion criteria they have added: 

14. Have any of the following ocular conditions at baseline:

  • Active or chronic corneal disorder, including but not limited to Sjogren's, Fuch's corneal dystrophy, history of corneal transplantation, active herpetic keratitis, as well as other active ocular conditions requiring ongoing therapy.
  • Any clinically significant corneal disease that prevents adequate monitoring of drug induced keratopathy.
  • Laser in-situ keratomileusis (LASIK) procedure performed within 1 year or less.
  • Cataract surgery within 3 months or less.
  • Patients will not be allowed to use contacts unless advised by an eye care provider for adverse event treatment during the study treatment.
Comment by jeffm34 on Apr 15, 2022 1:32am
An additional location has also been added. Mary Crowley cancer research in Dallas Texas
Comment by qwerty22 on Apr 15, 2022 9:39am
You are right about the ocular addition but when you look at the history of changes it shows they did an extensive rewrite on the whole inclusion/exclusion section and other parts. https://clinicaltrials.gov/ct2/history/NCT04706962?A=4&B=5&C=Side-by-Side#StudyPageTop  
Comment by jfm1330 on Apr 15, 2022 12:12pm
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677113/
Comment by qwerty22 on Apr 15, 2022 12:29pm
The thing I think I heard Christian sorta mumbled at the financial year report in Feb was that the 3 AEs in the 420 group which were on top of the neutropenia DLT were all the type of side effects seen with docetaxel. It's so vague and they've used up all their trust points with me so who knows exactly what that means. I guess it all comes down to manageability.  
Comment by Wino115 on Apr 15, 2022 12:45pm
That NCI update likely means they got no further questions back from the FDA like they stated, so it's all a go for the basket trial.  Have to assume many of the additional details are based on what they and the investigators have learned thus far. JFM should like the fac they've added a number of  exclusions to control the entry types even further which theoretically should ...more  
Comment by qwerty22 on Apr 16, 2022 12:33pm
CRO - contract research organization
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities